United States

People: Vivendi SA (VIV.PA)

VIV.PA on Paris Stock Exchange

11:35am EDT
Change (% chg)

€-0.07 (-0.40%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Camus, Daniel 

Dr. Daniel Camus has been an Independent Member of the Supervisory Board at Vivendi SA since April 29, 2010. He is also a Member of the Company’s Strategic Committee and Chairman of the Audit Committee. He obtained a Masters of Business Administration in Finance and Economics from the Institut d'Etudes Politiques de Paris and holds a Doctorate of Science n Economics and Management Sciences from Universite Paris-Sorbonne (Paris IV). He also received a Masters degree from Nancy-Universite. He spent most of his career in the chemical and pharmaceutical industry, primarily outside of France. During his more than 25 years with the Hoechst and the Aventis groups, he spent the major part of his career in North America before returning to Europe, where held the position of Group Chief Financial Officer for over 15 years, first as a member of the Management Board of the Roussel Uclaf SA group in Paris, then successively as group Chief Financial Officer of Hoechst Marion Roussel in Bridgewater (USA) and Frankfurt/Main (Germany) and as Chief Financial Officer and member of the Management Board of Aventis Pharma AG, following the merger of Hoechst and Rhone Poulenc. In 2002, he joined the EDF Group where, as Chief Financial Officer, he directed the financial transformation that led to the admission of new shareholders to the company in 2005. Until late 2010, he was Executive Director of the EDF Group in charge of strategy and international activities. In June 2011, he became a Senior Advisor at Roland Berger Strategy Consultants in Paris and Dusseldorf. Since August 2012, he has been the Financial Director and Member of the Executive Committee of the Global Fund in Geneva. Dr. Camus also serves as Member of the Board of Directors at Valeo SA and Cameco Corp., as well as Member of the Supervisory Board at Morphosy AG and SGL Carbon AG.

Basic Compensation

Total Annual Compensation, EUR 124,891
Restricted Stock Awards, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 124,891

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --